Welcome to our dedicated page for Paysign SEC filings (Ticker: PAYS), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Paysign, Inc. filings document formal disclosures for a Nevada public company providing patient affordability programs, donor compensation solutions, engagement and management platforms, and integrated payment processing. Recent Form 8-K reports furnish operating results and financial-condition updates tied to quarterly and annual earnings releases.
The company’s proxy materials describe annual meeting matters, director elections, auditor ratification, board and committee responsibilities, executive compensation, and beneficial ownership of Paysign securities. Other current reports include Regulation FD disclosures related to stockholder derivative action settlement materials, giving the filing record governance, litigation, ownership and reporting-context coverage in addition to financial results.
Paysign, Inc. Chief Legal Officer Robert Strobo reported compensation-related stock activity. On May 27, 2026, he received a grant of 66,667 shares of common stock at no cost, reflecting the vesting of performance-based restricted stock tied to specific earnings targets. On the same date, 39,235 shares of common stock were withheld by the company to cover tax obligations related to this vesting. Following these transactions, Strobo directly held 393,957 shares of Paysign common stock. The disposition was a tax-withholding mechanism rather than an open-market sale.
Paysign, Inc. executive Joan M. Herman, EVP of Operations and a director, reported an open-market sale of 22,534 shares of common stock at a weighted average price of $7.0133 per share on May 26, 2026. These shares were sold in multiple trades at prices ranging from $7.0001 to $7.0249 per share. After this transaction, Herman directly holds 813,989 shares of Paysign common stock. The sale was carried out under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating the trades were scheduled in advance.
Paysign, Inc. CEO Mark Newcomer reported equity compensation activity. On May 20, 2026, he received a grant of 133,334 shares of Common Stock at no cost, tied to performance-based restricted stock that vested based on specific defined earnings targets.
To cover tax withholding obligations from this vesting, 78,701 shares were disposed of back to the issuer at $6.15 per share. After these transactions, Newcomer directly holds 9,084,062 shares of Paysign common stock, reflecting a net increase in his equity position.
Paysign, Inc. Chief Payments Officer Matthew Louis Lanford reported routine equity compensation activity. On May 18, 2026, performance-based restricted stock vested based on defined earnings targets, resulting in a grant of 22,222 shares of common stock. To cover related tax obligations, 12,755 shares were withheld by the company at $5.865 per share. After these transactions, Lanford directly held 202,920 shares of Paysign common stock. These events reflect compensation vesting and tax withholding rather than open-market buying or selling.
Paysign, Inc. executive Joan M. Herman reported routine equity-compensation related transactions in company common stock. On May 13, 2026, performance-based restricted stock vested based on specific defined earnings targets, resulting in an award of 11,111 shares.
To cover associated tax withholding obligations from this vesting, 6,171 shares were withheld by the issuer at a reference price of $5.83 per share. These are not open-market sales or purchases, but mechanical entries tied to compensation. After these transactions, Herman directly holds 842,694 shares of Paysign common stock.
Paysign, Inc. delivered a very strong first quarter of 2026, with revenue of $28,038,424, up 50.8% from $18,598,149 a year earlier. Growth was driven by plasma revenue rising to $11,748,611 and pharma revenue to $15,679,452.
Net income more than doubled to $5,438,918 from $2,586,100, lifting net margin to 19.4% from 13.9%. Diluted EPS increased to $0.09 from $0.05. Adjusted EBITDA rose to $10,588,294, with Adjusted EBITDA margin expanding to 37.8% from 26.7%.
Gross dollar volume loaded on cards increased to $514 million from $407 million, reflecting higher activity across programs. Cash (excluding restricted cash) stood at $20,545,119, and management believes this, together with forecast cash flows, will sustain operations for the next twenty‑four months.
Paysign, Inc. held its Annual Meeting of stockholders on May 8, 2026, where shareholders voted on board elections and auditor ratification. Seven director nominees, including Mark R. Newcomer and Dennis L. Triplett, were elected to serve until the 2027 annual meeting.
Shareholders also ratified Baker Tilly US, LLP as Paysign’s independent registered public accounting firm for the fiscal year ending December 31, 2026, with 38,429,068 votes for, 279 against, and 96,029 abstentions, plus 641,671 broker non-votes.
Paysign, Inc. reported a strong first quarter of 2026, with revenue rising 50.8% to $28.04 million, driven by rapid growth in patient affordability and plasma programs. Pharma revenue grew 81.9% to $15.68 million, while plasma revenue increased 24.9% to $11.75 million.
Operating margin expanded to 23.8% from 13.4%, and net income more than doubled to $5.44 million, or $0.09 per diluted share. Adjusted EBITDA rose 113.4% to $10.59 million, with a 37.8% margin. The company ended the quarter with $20.55 million in unrestricted cash, no bank debt, and reaffirmed 2026 guidance, targeting revenue growth of 30–35% and higher margins.
Paysign, Inc. executive Joan M. Herman, EVP of Operations and a director, sold 6,667 shares of common stock in an open-market transaction on May 4, 2026 at a weighted average price of $7.0102 per share.
The transaction was effected under a pre-arranged Rule 10b5-1 trading plan adopted on September 12, 2025, indicating it was scheduled in advance. Following this sale, Herman directly holds 831,583 shares of Paysign common stock.
Paysign, Inc. will hold its 2026 annual shareholder meeting on May 8, 2026 at M Resort Spa Casino in Henderson, Nevada. Holders of 55,185,394 shares as of March 9, 2026 may vote to elect seven directors and ratify Baker Tilly US, LLP as auditor for 2026.
Directors and executive officers control 11,896,511 shares, or about 21.6% of voting power. The board reports a majority of independent directors and fully independent audit, compensation, and nominating committees.
Executive pay is heavily equity-based. In 2025 the CEO received total compensation of $2.75 million, including 600,000 restricted shares valued at $1.40 million, while other named executives also received large multi‑year restricted stock grants tied to service and achieved earnings targets.